de Jonge, Maja J. A.

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J.-Y., et al. (2023) · Nature Medicine

Melanoma and MAPK PathwaysGastrointestinal Tumor Research and Treatment

Cited by 343

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

Kitzen, J. J. E. M., de Jonge, M. J. A., Lamers, C. H. J., Eskens, F. A. L. M., van der Biessen, D., van Doorn, L., ter Steeg, J., Brandely, M., Puozzo, C., & Verweij, J. (2009) · European Journal of Cancer

Natural Compounds in Disease TreatmentCell death mechanisms and regulation

Cited by 89